CVS Health Co. (NYSE:CVS) Shares Sold by Rothschild Investment LLC

Rothschild Investment LLC decreased its position in shares of CVS Health Co. (NYSE:CVS - Free Report) by 20.9% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 59,194 shares of the pharmacy operator's stock after selling 15,617 shares during the period. Rothschild Investment LLC's holdings in CVS Health were worth $4,010,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the stock. Dodge & Cox lifted its stake in CVS Health by 11.2% in the 4th quarter. Dodge & Cox now owns 70,105,899 shares of the pharmacy operator's stock valued at $3,147,054,000 after purchasing an additional 7,075,209 shares during the last quarter. Capital World Investors lifted its stake in CVS Health by 26.6% in the 4th quarter. Capital World Investors now owns 61,039,777 shares of the pharmacy operator's stock valued at $2,739,927,000 after purchasing an additional 12,819,148 shares during the last quarter. Geode Capital Management LLC raised its stake in shares of CVS Health by 2.6% during the fourth quarter. Geode Capital Management LLC now owns 27,051,540 shares of the pharmacy operator's stock valued at $1,211,582,000 after acquiring an additional 689,867 shares during the last quarter. Capital International Investors raised its stake in shares of CVS Health by 4.8% during the fourth quarter. Capital International Investors now owns 26,666,401 shares of the pharmacy operator's stock valued at $1,196,989,000 after acquiring an additional 1,212,126 shares during the last quarter. Finally, Pzena Investment Management LLC raised its stake in shares of CVS Health by 49.3% during the fourth quarter. Pzena Investment Management LLC now owns 19,610,579 shares of the pharmacy operator's stock valued at $880,319,000 after acquiring an additional 6,475,271 shares during the last quarter. Institutional investors own 80.66% of the company's stock.

CVS Health Stock Performance

Shares of CVS traded down $0.45 on Monday, reaching $63.60. The company's stock had a trading volume of 6,674,441 shares, compared to its average volume of 11,195,129. The company has a debt-to-equity ratio of 0.80, a current ratio of 0.81 and a quick ratio of 0.60. The stock has a market capitalization of $80.45 billion, a P/E ratio of 17.38, a PEG ratio of 0.98 and a beta of 0.60. The stock's 50 day simple moving average is $65.62 and its two-hundred day simple moving average is $59.67. CVS Health Co. has a 12-month low of $43.56 and a 12-month high of $72.51.

CVS Health (NYSE:CVS - Get Free Report) last released its earnings results on Thursday, May 1st. The pharmacy operator reported $2.25 EPS for the quarter, topping analysts' consensus estimates of $1.62 by $0.63. The company had revenue of $94.59 billion for the quarter, compared to analysts' expectations of $93.07 billion. CVS Health had a net margin of 1.24% and a return on equity of 9.11%. The firm's revenue was up 7.0% compared to the same quarter last year. During the same quarter last year, the business earned $1.31 EPS. Research analysts forecast that CVS Health Co. will post 5.89 earnings per share for the current fiscal year.

CVS Health Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Thursday, May 1st. Shareholders of record on Tuesday, April 22nd were given a dividend of $0.665 per share. This represents a $2.66 dividend on an annualized basis and a yield of 4.18%. The ex-dividend date was Tuesday, April 22nd. CVS Health's dividend payout ratio (DPR) is 63.48%.

Analyst Upgrades and Downgrades

CVS has been the subject of several analyst reports. Mizuho raised their price target on shares of CVS Health from $70.00 to $76.00 and gave the company an "outperform" rating in a research note on Wednesday, April 9th. Leerink Partners raised shares of CVS Health from a "market perform" rating to an "outperform" rating and lifted their target price for the stock from $55.00 to $75.00 in a research note on Thursday, February 13th. Wells Fargo & Company reissued an "overweight" rating and set a $84.00 target price (up previously from $76.00) on shares of CVS Health in a research note on Tuesday, May 6th. Royal Bank of Canada lifted their target price on shares of CVS Health from $74.00 to $81.00 and gave the stock an "outperform" rating in a research note on Monday, May 5th. Finally, Morgan Stanley reissued an "overweight" rating on shares of CVS Health in a research note on Tuesday, April 15th. Two analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $74.75.

Insider Buying and Selling at CVS Health

In other CVS Health news, SVP James David Clark sold 7,513 shares of the business's stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $66.35, for a total value of $498,487.55. Following the completion of the sale, the senior vice president now directly owns 8,394 shares of the company's stock, valued at $556,941.90. The trade was a 47.23% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 1.22% of the company's stock.

CVS Health Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.